디지털 패솔로지 시장 – 2029년까지의 세계 예측

조사회사 : MarketsandMarkets (마켓츠앤마켓츠)   출판년월 : 2024년07월

Digital Pathology Market – Global Forecast to 2029

디지털 패솔로지 시장 – 제품(스캐너, 소프트웨어, 스토리지 시스템), 타입(인간, 수의사), 용도(원격 상담, 트레이닝, 질병 진단, 창약), 최종 사용자(제약·바이오테크놀로지, 학술 기관, 병원)의 시장규모, 점유율, 동향 – 2029년까지의 세계 예측
Digital Pathology Market Size, Share & Trends by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) – Global Forecast to 2029

　　　　주문/문의　　　　조사회사/라이센스/납기안내

Report Overview

The global digital pathology market is projected to reach USD 2.0 billion by 2029 from USD 1.1 billion in 2024, at a CAGR of 13.1% from 2024 to 2029.

세계 디지털 패솔로지 시장은 2024년부터 2029년까지 13.1%의 CAGR로 성장했으며, 2024년 11억 달러에서 2029년까지 20억 달러에 이를 것으로 예측됩니다.

The growth of the market is fuelled due to advancements in technology, such as high-resolution scanners, sophisticated imaging software, and AI-powered analytics, significantly improve the accuracy and efficiency of pathology workflows. The increasing prevalence of chronic diseases, including cancer, necessitates rapid and precise diagnostic tools, which digital pathology readily provides. Moreover, the push towards personalized medicine and targeted therapies requires detailed tissue analysis that digital pathology can deliver.

“Scanners segment held the largest share in the global Digital Pathology market during the forecast period.”

On the basis type, the Digital Pathology market is segmented into scanners, software, and storage systems segment. The scanners segment accounted for the largest share of the product segment in 2023 because these devices are essential to the digital pathology process. Scanners transform glass slides into high-resolution digital images, allowing pathologists to view and analyze specimens on computer screens. The critical role of scanners in enabling remote diagnostics drives their demand, as they allow pathologists to review cases from any location, thereby improving accessibility and efficiency in pathology services. Furthermore, advancements in scanner technology, such as higher resolution imaging and faster scanning speeds, enhance diagnostic accuracy and workflow efficiency, making them a valuable investment for laboratories and healthcare facilities.

“By type, human pathology holds the largest share during the forecast period.”

Based on type, the Digital Pathology market is segmented into human pathology and veterinary pathology.  Human pathology holds the largest share during forecast period. Firstly, the rising prevalence of chronic diseases such as cancer demands advanced diagnostic tools for accurate and timely detection. Digital pathology offers significant advantages over traditional methods, including enhanced image analysis, superior storage and retrieval capabilities, and the ease of sharing digital slides for remote consultations and second opinions. Moreover, technological advancements like artificial intelligence and machine learning are increasingly being integrated into digital pathology, equipping pathologists with powerful tools for improved diagnostic accuracy and efficiency.

“The Drug Discovery segment accounted for the largest share of the global Digital Pathology market during the forecast period.”

Based on application, the Digital Pathology market is segmented into drug discovery, disease diagnosis, training and education segment. The drug discovery segment accounted for the largest share of the application segment in 2023.  This is due to the accuracy of the drug development process. Consequently, integrating digital pathology into drug discovery workflows significantly boosts productivity, drives innovation, and shortens the time-to-market for new drugs, cementing its dominant position in this market segment.

“Pharmaceutical and biotechnology companies are largest end users of the Digital Pathology market.”

Based on end users, the Digital Pathology market is segmented into pharmaceutical and biotechnology companies, hospital and reference laboratories, and academic and research institutes. The pharmaceutical and biotechnology companies held the largest share in 2023. The scalability of digital pathology solutions aligns well with the large volumes of samples that pharmaceutical and biotechnology companies handle, providing them with a critical tool to accelerate research and development, ultimately leading to faster time-to-market for new therapies. This combination of improved efficiency, accuracy, and collaboration makes digital pathology an invaluable asset for these companies, thus driving their dominant market share.

“North America dominates the global Digital Pathology market.”

The Digital Pathology market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023, North America accounted for the largest share of the Digital Pathology market. This is due to its advanced healthcare infrastructure and significant investment in healthcare technologies, allowing for the adoption of cutting-edge digital pathology systems. Also, regulatory frameworks in countries like the US and Canada are supportive of the adoption of advanced medical technologies, ensuring a streamlined approval process for digital pathology solutions.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level (35%), Director-level (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report

• Danaher Corporation (US)
• Koninklijke Philips N.V. (Netherlands)
•  Hamamatsu Photonics K.K. (Japan)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• 3DHISTECH (Hungary)
• Apollo Enterprise Imaging (US)
• XIFIN, Inc. (US)
•  Huron Digital Pathology (Canada)
• Hologic, Inc. (US)
• Corista (US)
• Indica Labs Inc. (US)
• Objective Pathology Services Limited (Canada)
• Sectra AB (Sweden)
• OptraSCAN (US)
• Akoya Biosciences, Inc. (US)
• Glencoe Software, Inc. (US)
• Aiforia (Finland)
• Paige AI, Inc. (US)
• Fujifilm Holdings Corporation (Japan)
•  Proscia Inc. (US)
• KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China)
• Mikroscan Technologies, Inc. (US)
•  PathAI (US)
•  Motic Digital Pathology (US)
• Kanteron Systems (Spain)

Research Coverage

This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (advancements in image analysis algorithms, artificial intelligence (AI) applications for pattern recognition, and cloud-based solutions that enhance scalability and accessibility), restrains (lack of trained pathologits and high capital investment), challenges (data privacy concerns), opportunities (expansion in emerging market and personalized medicine and biomarker discovery) are contributing the growth of the digital pathology market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market.
• Market Development: Comprehensive information on the lucrative emerging markets, products, type, application, end-user, and region.
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the digital pathology market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology Market.

Table of Contents

1            INTRODUCTION            29

1.1         STUDY OBJECTIVES      29

1.2         MARKET DEFINITION   29

1.2.1      INCLUSIONS & EXCLUSIONS     30

1.3         MARKET SCOPE             31

1.3.1      MARKETS COVERED     31

1.3.2      YEARS CONSIDERED     32

1.3.3      CURRENCY CONSIDERED          32

1.4         STAKEHOLDERS            32

1.5         SUMMARY OF CHANGES            33

2            RESEARCH METHODOLOGY     34

2.1         RESEARCH APPROACH 34

2.1.1      SECONDARY DATA       35

2.1.1.1   Key data from secondary sources     36

2.1.2      PRIMARY DATA 37

2.1.2.1   Key data from primary sources         38

2.1.2.2   Key industry insights          38

2.2         RESEARCH METHODOLOGY DESIGN    39

2.3         MARKET SIZE ESTIMATION       40

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    46

2.5         RESEARCH ASSUMPTIONS         47

2.6         MARKET ASSUMPTIONS             47

2.6.1      OVERALL STUDY ASSUMPTIONS            48

2.7         RISK ASSESSMENT         48

2.8         RESEARCH LIMITATIONS           48

2.8.1      METHODOLOGY-RELATED LIMITATIONS         48

2.8.2      SCOPE-RELATED LIMITATIONS             48

3            EXECUTIVE SUMMARY 49

4            PREMIUM INSIGHTS      53

4.1         DIGITAL PATHOLOGY MARKET OVERVIEW      53

4.2         NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2023)           54

4.3         DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           55

4.4         DIGITAL PATHOLOGY MARKET: REGIONAL MIX            56

5            MARKET OVERVIEW     57

5.1         INTRODUCTION            57

5.2         MARKET DYNAMICS     57

5.2.1      DRIVERS            57

5.2.1.1   Rising incidence of cancer and chronic diseases           57

5.2.1.2   Increasing adoption of digital pathology solutions to enhance lab efficiency              59

5.2.1.3   Growing applications in drug development and companion diagnostics    60

5.2.1.4   Rising awareness of early cancer diagnosis in emerging markets 61

5.2.2      RESTRAINTS     62

5.2.2.1   High cost of digital pathology systems            62

5.2.3      OPPORTUNITIES           62

5.2.3.1   Introduction of affordable scanners for private pathology practices          62

5.2.3.2   Growing preference for personalized medicine            62

5.2.3.3   High growth potential of emerging economies             64

5.2.4      CHALLENGES   64

5.2.4.1   Shortage of skilled pathologists        64

5.3         INDUSTRY TRENDS       65

5.3.1      TELEPATHOLOGY         65

5.3.2      MULTIPLEXING             65

5.4         TECHNOLOGY ANALYSIS           65

5.4.1      KEY TECHNOLOGIES    65

5.4.1.1   AI in digital pathology       65

5.4.1.2   Label-free imaging in digital pathology          66

5.4.1.3   Computational image analysis in digital pathology       66

5.4.2      ADJACENT TECHNOLOGIES      66

5.4.2.1   Genomic sequencing          66

5.4.3      COMPLEMENTARY TECHNOLOGIES     67

5.4.3.1   Molecular imaging             67

5.5         PRICING ANALYSIS        67

5.5.1      AVERAGE SELLING PRICE TREND, BY REGION  68

5.5.2      AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT              68

5.6         VALUE CHAIN ANALYSIS            68

5.7         ECOSYSTEM ANALYSIS 69

5.8         PORTER’S FIVE FORCES ANALYSIS         70

5.8.1      THREAT OF NEW ENTRANTS    71

5.8.2      THREAT OF SUBSTITUTES         71

5.8.3      BARGAINING POWER OF SUPPLIERS     71

5.8.4      BARGAINING POWER OF BUYERS           72

5.8.5      INTENSITY OF COMPETITIVE RIVALRY 72

5.9         REGULATORY LANDSCAPE       72

5.9.1      REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 72

5.9.2      REGULATORY ANALYSIS            73

5.9.2.1   North America     73

5.9.2.1.1 US         73

5.9.2.1.2 Canada  74

5.9.2.2   Europe  74

5.9.2.3   Asia Pacific          76

5.9.2.3.1 Japan     76

5.9.2.3.2 China     76

5.9.2.3.3 India      77

5.10       HS CODES FOR DIGITAL PATHOLOGY SCANNERS          77

5.11       PATENT ANALYSIS        78

5.11.1    PATENT PUBLICATION TRENDS            78

5.11.2    JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS 78

5.11.3    MAJOR PATENTS           79

5.12       CASE STUDY ANALYSIS 81

5.13       KEY CONFERENCES & EVENTS, 2024–2025           82

5.14       KEY STAKEHOLDERS & BUYING CRITERIA          83

5.14.1    KEY STAKEHOLDERS IN BUYING PROCESS         83

5.14.2    BUYING CRITERIA         84

5.15       END-USER ANALYSIS    85

5.15.1    UNMET NEEDS 85

5.15.2    END-USER EXPECTATIONS       86

5.16       BUSINESS MODEL ANALYSIS     87

5.17       INVESTMENT & FUNDING SCENARIO    87

5.18       IMPACT OF GENERATIVE AI ON DIGITAL PATHOLOGY MARKET              88

5.18.1    TOP USE CASES & MARKET POTENTIAL             88

5.18.1.1 Key Use Cases     89

5.18.2    CASE STUDIES OF GENERATIVE AI IMPLEMENTATION 89

5.18.2.1 Case Study 1: Healthcare – Enhancing Medical Imaging             89

5.18.2.2 Case study 2: Combining generative AI with biosensors and lab-on-a-chip technology           90

5.18.2.3 Case study 3: Impact of Gen AI-based Digital pathology: the Korean experience              90

5.18.2.4 AI in pathology market      91

5.18.2.5 Tissue diagnostics market  91

5.18.2.6 Anatomic pathology market             92

5.18.3    USER READINESS AND IMPACT ASSESSMENT    92

5.18.3.1 User readiness     92

5.18.3.1.1            Pharmaceutical & biotechnology companies  92

5.18.3.1.2            Hospitals & reference laboratories   92

5.18.3.1.3            Academic & research institutes        93

5.18.3.2 Impact assessment             93

5.18.3.2.1            Pharmaceutical & biotechnology companies  93

5.18.3.2.2            Hospitals & reference laboratories   93

5.18.3.2.3            Academic & research institutes        94

6            DIGITAL PATHOLOGY MARKET, BY PRODUCT 95

6.1         INTRODUCTION            96

6.2         SCANNERS        96

6.2.1      BRIGHTFIELD SCANNERS          100

6.2.1.1   Cost-efficient features to boost demand         100

6.2.2      FLUORESCENCE SCANNERS      101

6.2.2.1   Ability to detect cellular structures and biomarkers to fuel uptake            101

6.2.3      OTHER SCANNERS        103

6.3         SOFTWARE, BY TYPE    104

6.3.1      INTEGRATED SOFTWARE          106

6.3.1.1   Single & effective suite for multiple applications to propel market            106

6.3.2      STANDALONE SOFTWARE         107

6.3.2.1   Information management software  109

6.3.2.1.1 Management of image repositories to fuel uptake         109

6.3.2.2   Image analysis software     111

6.3.2.2.1 Ability to automate quantitative evaluation to support market growth      111

6.4         SOFTWARE, BY DEPLOYMENT MODEL 112

6.4.1      CLOUD-BASED MODEL 113

6.4.1.1   Benefits of cloud-based models and ease of access to drive market           113

6.4.2      ON-PREMISE MODEL    115

6.4.2.1   High data security and integration with HCIT solutions to fuel uptake     115

6.4.3      HYBRID MODEL             117

6.4.3.1   Combined flexibility to support market growth            117

6.5         STORAGE SYSTEMS       119

6.5.1      GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET 119

7            DIGITAL PATHOLOGY MARKET, BY TYPE          121

7.1         INTRODUCTION            122

7.2         HUMAN PATHOLOGY   122

7.2.1      INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET              122

7.3         VETERINARY PATHOLOGY        123

7.3.1      IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH        123

8            DIGITAL PATHOLOGY MARKET, BY APPLICATION        125

8.1         INTRODUCTION            126

8.2         DRUG DISCOVERY         127

8.2.1      INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET              127

8.3         DISEASE DIAGNOSIS     128

8.3.1      INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND           128

8.4         TRAINING & EDUCATION          130

8.4.1      ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH    130

9            DIGITAL PATHOLOGY MARKET, BY END USER  131

9.1         INTRODUCTION            132

9.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   132

9.2.1      INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET            132

9.3         HOSPITALS AND REFERENCE LABORATORIES  134

9.3.1      HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND              134

9.4         ACADEMIC & RESEARCH INSTITUTES   136

9.4.1      INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH    136

10          DIGITAL PATHOLOGY MARKET, BY REGION     138

10.1       INTRODUCTION            139

10.2       NORTH AMERICA          139

10.2.1    US         144

10.2.1.1 Favorable reimbursements for diagnostics to drive market         144

10.2.2    CANADA            148

10.2.2.1 Growing awareness of early cancer detection & diagnosis to drive market 148

10.3       EUROPE             152

10.3.1    GERMANY         157

10.3.1.1 High healthcare expenditure and supportive research initiatives to drive market              157

10.3.2    UK         161

10.3.2.1 Government funding investments for pathology services to fuel market   161

10.3.3    SWEDEN            165

10.3.3.1 Increasing prevalence of chronic diseases to support market growth         165

10.3.4    DENMARK         169

10.3.4.1 Increasing deployment of digital pathology solutions to support market growth              169

10.3.5    FRANCE             173

10.3.5.1 Increasing government funding and favorable insurance system to drive adoption              173

10.3.6    SPAIN   176

10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand 176

10.3.7    ITALY   179

10.3.7.1 Integration of AI & ML to support market growth        179

10.3.8    REST OF EUROPE           182

10.4       ASIA PACIFIC    185

10.4.1    CHINA  189

10.4.1.1 Increasing establishment of hospitals and reference laboratories to drive market              189

10.4.2    JAPAN  192

10.4.2.1 Advanced healthcare infrastructure to support market growth    192

10.4.3    INDIA   196

10.4.3.1 Growth in pharmaceutical industry to propel market    196

10.4.4    REST OF ASIA PACIFIC  200

10.5       LATIN AMERICA             203

10.5.1    BRAZIL 206

10.5.1.1 High adoption of POC testing to drive market             206

10.5.2    MEXICO             210

10.5.2.1 Growth in companion diagnostics to fuel uptake          210

10.5.3    REST OF LATIN AMERICA          213

10.6       MIDDLE EAST & AFRICA             216

10.6.1    IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH        216

10.6.2    GCC COUNTRIES           220

10.6.3    REST OF MIDDLE EAST & AFRICA           223

11          COMPETITIVE LANDSCAPE       227

11.1       OVERVIEW        227

11.2       KEY PLAYER STRATEGY/RIGHT TO WIN             227

11.2.1    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET 228

11.3       REVENUE ANALYSIS      229

11.4       MARKET SHARE ANALYSIS         230

11.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   232

11.5.1    STARS  232

11.5.2    EMERGING LEADERS    232

11.5.3    PERVASIVE PLAYERS     233

11.5.4    PARTICIPANTS 233

11.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      234

11.5.5.1 Product footprint 235

11.5.5.2 Application footprint         236

11.5.5.3 End-user footprint             237

11.5.5.4 Region footprint  238

11.6       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          239

11.6.1    PROGRESSIVE COMPANIES       239

11.6.2    RESPONSIVE COMPANIES          239

11.6.3    DYNAMIC COMPANIES 239

11.6.4    STARTING BLOCKS       239

11.6.5    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023             241

11.7       VALUATION & FINANCIAL METRICS      243

11.8       BRAND/SOFTWARE COMPARATIVE ANALYSIS  244

11.9       COMPETITIVE SCENARIO          245

11.9.1    PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS       245

11.9.2    DEALS  246

11.9.3    OTHER DEVELOPMENTS           247

12          COMPANY PROFILES    248

12.1       KEY COMPANIES            248

12.1.1    DANAHER CORPORATION         248

12.1.1.1 Business overview 248

12.1.1.2 Products offered  249

12.1.1.3 Recent developments         250

12.1.1.3.1            Product enhancements      250

12.1.1.4 MnM view           250

12.1.1.4.1            Key strengths       250

12.1.1.4.2            Strategic choices  250

12.1.1.4.3            Weaknesses and competitive threats 250

12.1.2    KONINKLIJKE PHILIPS N.V.        251

12.1.2.1 Business overview 251

12.1.2.2 Products offered  252

12.1.2.3 Recent developments         253

12.1.2.3.1            Product launches 253

12.1.2.3.2            Deals     253

12.1.2.4 MnM view           254

12.1.2.4.1            Key strengths       254

12.1.2.4.2            Strategic choices  254

12.1.2.4.3            Weaknesses and competitive threats 254

12.1.3    HAMAMATSU PHOTONICS K.K. 255

12.1.3.1 Business overview 255

12.1.3.2 Products offered  256

12.1.3.3 Recent developments         257

12.1.3.3.1            Product approvals 257

12.1.3.3.2            Deals     257

12.1.3.4 MnM view           258

12.1.3.4.1            Key strengths       258

12.1.3.4.2            Strategic choices  258

12.1.3.4.3            Weaknesses and competitive threats 258

12.1.4    F. HOFFMANN-LA ROCHE LTD. 259

12.1.4.1 Business overview 259

12.1.4.2 Products offered  260

12.1.4.3 Recent developments         261

12.1.4.3.1            Product Launches & approvals        261

12.1.4.3.2            Deals     261

12.1.4.4 MnM view           262

12.1.4.4.1            Key strengths       262

12.1.4.4.2            Strategic choices  262

12.1.4.4.3            Weaknesses and competitive threats 262

12.1.5    SECTRA AB        263

12.1.5.1 Business overview 263

12.1.5.2 Products offered  264

12.1.5.3 Recent developments         265

12.1.5.3.1            Deals     265

12.1.5.3.2            Other developments          266

12.1.5.4 MnM view           267

12.1.5.4.1            Key strengths       267

12.1.5.4.2            Strategic choices  267

12.1.5.4.3            Weaknesses and competitive threats 267

12.1.6    AKOYA BIOSCIENCES, INC.        268

12.1.6.1 Business overview 268

12.1.6.2 Products offered  270

12.1.6.3 Recent developments         270

12.1.6.3.1            Product Launches & approvals        270

12.1.6.3.2            Deals     271

12.1.7    FUJIFILM HOLDINGS CORPORATION    272

12.1.7.1 Business overview 272

12.1.7.2 Products offered  273

12.1.7.3 Recent developments         274

12.1.7.3.1            Deals     274

12.1.8    HOLOGIC, INC. 275

12.1.8.1 Business overview 275

12.1.8.2 Products offered  276

12.1.8.3 Recent developments         277

12.1.8.3.1            Product approvals 277

12.1.9    3DHISTECH LTD.           278

12.1.9.1 Business overview 278

12.1.9.2 Products offered  278

12.1.9.3 Recent developments         279

12.1.9.3.1            Product launches & enhancements   279

12.1.9.3.2            Other developments          279

12.1.10  APOLLO ENTERPRISE IMAGING CORP. 280

12.1.10.1             Business overview 280

12.1.10.2             Products offered  280

12.1.10.3             Recent developments         281

12.1.10.3.1          Product enhancements      281

12.1.10.3.2          Deals     281

12.1.11  XIFIN, INC.         282

12.1.11.1             Business overview 282

12.1.11.2             Products offered  282

12.1.11.3             Recent developments         283

12.1.11.3.1          Product launches 283

12.1.11.3.2          Deals     283

12.1.12  HURON DIGITAL PATHOLOGY 284

12.1.12.1             Business overview 284

12.1.12.2             Products offered  284

12.1.12.3             Recent developments         285

12.1.12.3.1          Product approvals 285

12.1.12.3.2          Deals     285

12.1.12.3.3          Other developments          285

12.1.13  CORISTA            286

12.1.13.1             Business overview 286

12.1.13.2             Products offered  286

12.1.13.3             Recent developments         287

12.1.13.3.1          Deals     287

12.1.13.3.2          Other developments          287

12.1.14  INDICA LABS    288

12.1.14.1             Business overview 288

12.1.14.2             Products offered  288

12.1.14.3             Recent developments         289

12.1.14.3.1          Product launches & approvals          289

12.1.14.3.2          Deals     290

12.1.15  OBJECTIVE PATHOLOGY SERVICES       291

12.1.15.1             Business overview 291

12.1.15.2             Products offered  291

12.1.16  OPTRASCAN, INC.          292

12.1.16.1             Business overview 292

12.1.16.2             Products offered  292

12.1.16.3             Recent developments         293

12.1.16.3.1          Product launches & approvals          293

12.1.16.3.2          Deals     293

12.1.17  GLENCOE SOFTWARE, INC.       294

12.1.17.1             Business overview 294

12.1.17.2             Products offered  294

12.1.17.3             Recent developments         295

12.1.17.3.1          Product enhancements      295

12.1.18  AIFORIA TECHNOLOGIES OY    296

12.1.18.1             Business overview 296

12.1.18.2             Products offered  296

12.1.18.3             Recent developments         297

12.1.18.3.1          Deals     297

12.1.19  PAIGE AI, INC.   298

12.1.19.1             Business overview 298

12.1.19.2             Products offered  298

12.1.19.3             Recent developments         299

12.1.19.3.1          Product launches & enhancements   299

12.1.19.3.2          Deals     299

12.1.20  PROSCIA, INC.   301

12.1.20.1             Business overview 301

12.1.20.2             Products offered  301

12.1.20.3             Recent developments         302

12.1.20.3.1          Product enhancements & approvals 302

12.1.20.3.2          Deals     302

12.2       OTHER PLAYERS           304

12.2.1    PATHAI 304

12.2.2    KONFOONG BIOTECH INTERNATIONAL CO., LTD.        305

12.2.3    MIKROSCAN TECHNOLOGIES, INC.        305

12.2.4    MOTIC DIGITAL PATHOLOGY  306

12.2.5    KANTERON SYSTEMS   307

12.2.6    MORPHLE LABS INC.     307

13          APPENDIX         308

13.1       DISCUSSION GUIDE      308

13.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             313

13.3       CUSTOMIZATION OPTIONS      315

13.4       RELATED REPORTS       315

13.5       AUTHOR DETAILS         316

LIST OF TABLES

TABLE 1             FACTOR ANALYSIS        43

TABLE 2             RISK ASSESSMENT         48

TABLE 3             INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)        59

TABLE 4             US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES (2008−2020)      63

TABLE 5             NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020      64

TABLE 6             AVERAGE SELLING PRICE TREND OF DIGITAL PATHOLOGY PRODUCTS, BY REGION             68

TABLE 7             AVERAGE SELLING PRICE OF DIGITAL PATHOLOGY PRODUCTS       68

TABLE 8             DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES              70

TABLE 9             REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          72

TABLE 10           US FDA: MEDICAL DEVICE CLASSIFICATION     73

TABLE 11           US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              73

TABLE 12           CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS           74

TABLE 13           EUROPE: CLASSIFICATION OF IVD DEVICES      75

TABLE 14           JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA              76

TABLE 15           CHINA: CLASSIFICATION OF MEDICAL DEVICES             77

TABLE 16           HS CODE: DIGITAL PATHOLOGY SCANNER       77

TABLE 17           CASE STUDY 1: ASSESSING IMAGE QUALITY FOR COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX              81

TABLE 18           CASE STUDY 2: PROMOTION OF PATHOLOGY WORKFLOW EFFICIENCY      81

TABLE 19           CASE STUDY 3: INTEGRATION OF ARTIFICIAL INTELLIGENCE IN DIGITAL PATHOLOGY          82

TABLE 20          DIGITAL PATHOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024−2025         82

TABLE 21           STAKEHOLDERS IN BUYING PROCESS: DEFINITIONS     83

TABLE 22           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY, BY PRODUCT    83

TABLE 23           KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS              84

TABLE 24           UNMET NEEDS IN DIGITAL PATHOLOGY MARKET        85

TABLE 25           END-USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET              86

TABLE 26           DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)          96

TABLE 27           SCANNING MAGNIFICATION AND APPLICATIONS         97

TABLE 28           DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS           97

TABLE 29           DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       98

TABLE 30           DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY COUNTRY, 2022–2029 (USD MILLION)            99

TABLE 31           BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS              100

TABLE 32           BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 101

TABLE 33           FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS           102

TABLE 34           FLUORESCENCE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102

TABLE 35           OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS              103

TABLE 36           OTHER SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          103

TABLE 37           DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS           104

TABLE 38           DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       105

TABLE 39           DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY COUNTRY, 2022–2029 (USD MILLION)            105

TABLE 40           INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS              106

TABLE 41           INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107

TABLE 42           STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)          108

TABLE 43           STANDALONE SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108

TABLE 44           INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS         109

TABLE 45           INFORMATION MANAGEMENT SOFTWARE MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            110

TABLE 46           IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS           111

TABLE 47           IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     112

TABLE 48           DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    113

TABLE 49           CLOUD-BASED SOFTWARE OFFERED BY KEY MARKET PLAYERS           113

TABLE 50           CLOUD-BASED MODEL MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114

TABLE 51           ON-PREMISE SOFTWARE OFFERED BY KEY MARKET PLAYERS              115

TABLE 52           ON-PREMISE MODEL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          116

TABLE 53           HYBRID SOFTWARE OFFERED BY KEY MARKET PLAYERS              117

TABLE 54           HYBRID MODEL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          118

TABLE 55           STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS              119

TABLE 56           DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS,

BY COUNTRY, 2022–2029 (USD MILLION)            120

TABLE 57           DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)          122

TABLE 58           HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     123

TABLE 59           VETERINARY DIGITAL PATHOLOGY MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            124

TABLE 60           DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 126

TABLE 61           SOFTWARE IMPACT ANALYSIS, BY APPLICATION           126

TABLE 62           DIGITAL PATHOLOGY APPLICATIONS IN DRUG DISCOVERY              127

TABLE 63           DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY,

BY COUNTRY, 2022–2029 (USD MILLION)            128

TABLE 64           DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS,

BY COUNTRY, 2022–2029 (USD MILLION)            129

TABLE 65          DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION,

BY COUNTRY, 2022–2029 (USD MILLION)            130

TABLE 66           DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)          132

TABLE 67           SOFTWARE IMPACT ANALYSIS, BY END USER    132

TABLE 68           DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)              133

TABLE 69           DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS       134

TABLE 70           DIGITAL PATHOLOGY MARKET FOR HOSPITALS AND REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)  135

TABLE 71           DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY COUNTRY, 2022–2029 (USD MILLION)            137

TABLE 72           DIGITAL PATHOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)          139

TABLE 73           NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          141

TABLE 74           NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          141

TABLE 75           NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       141

TABLE 76           NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       142

TABLE 77           NORTH AMERICA: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       142

TABLE 78           NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    142

TABLE 79           NORTH AMERICA: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       143

TABLE 80           NORTH AMERICA: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     143

TABLE 81           NORTH AMERICA: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            143

TABLE 82           US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              144

TABLE 83           US: KEY MACROINDICATORS    145

TABLE 84           US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 145

TABLE 85           US: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       145

TABLE 86           US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       146

TABLE 87           US: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 146

TABLE 88           US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    146

TABLE 89           US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)          147

TABLE 90           US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     147

TABLE 91           US: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 147

TABLE 92           CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              148

TABLE 93           CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY              149

TABLE 94           CANADA: KEY MACROINDICATORS       149

TABLE 95           CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     150

TABLE 96           CANADA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       150

TABLE 97           CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       150

TABLE 98           CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     151

TABLE 99           CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      151

TABLE 100         CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 151

TABLE 101         CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          152

TABLE 102         CANADA: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          152

TABLE 103         EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     154

TABLE 104         EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     154

TABLE 105         EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       155

TABLE 106         EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       155

TABLE 107         EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     155

TABLE 108         EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    156

TABLE 109         EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 156

TABLE 110         EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          156

TABLE 111         EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          157

TABLE 112         GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040      158

TABLE 113         GERMANY: KEY MACROINDICATORS    158

TABLE 114         GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          158

TABLE 115         GERMANY: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       159

TABLE 116         GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       159

TABLE 117         GERMANY: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       159

TABLE 118         GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      160

TABLE 119         GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)     160

TABLE 120         GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          160

TABLE 121         GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          161

TABLE 122         UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040            162

TABLE 123         UK: KEY MACROINDICATORS   162

TABLE 124         UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 163

TABLE 125         UK: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       163

TABLE 126         UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       163

TABLE 127         UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 164

TABLE 128         UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      164

TABLE 129         UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)          164

TABLE 130         UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     165

TABLE 131         UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 165

TABLE 132         SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              166

TABLE 133         SWEDEN: KEY MACROINDICATORS       166

TABLE 134         SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          166

TABLE 135         SWEDEN: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       167

TABLE 136         SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       167

TABLE 137         SWEDEN: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       167

TABLE 138         SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      168

TABLE 139         SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 168

TABLE 140         SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          168

TABLE 141         SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          169

TABLE 142         DENMARK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040      170

TABLE 143         DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          170

TABLE 144         DENMARK: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       170

TABLE 145         DENMARK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       171

TABLE 146         DENMARK: STANDALONE SOFTWARE MARKET, BY TYPE,

2022–2029 (USD MILLION)          171

TABLE 147         DENMARK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      171

TABLE 148         DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)     172

TABLE 149         DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          172

TABLE 150         DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          172

TABLE 151         FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              173

TABLE 152         FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     174

TABLE 153         FRANCE: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       174

TABLE 154         FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       174

TABLE 155         FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     175

TABLE 156         FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      175

TABLE 157         FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 175

TABLE 158         FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          176

TABLE 159         FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          176

TABLE 160         SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     177

TABLE 161         SPAIN: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       177

TABLE 162         SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       177

TABLE 163         SPAIN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 178

TABLE 164         SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    178

TABLE 165         SPAIN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 178

TABLE 166         SPAIN: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          179

TABLE 167         SPAIN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     179

TABLE 168         ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     180

TABLE 169         ITALY: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       180

TABLE 170         ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       180

TABLE 171         ITALY: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 181

TABLE 172         ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      181

TABLE 173         ITALY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 181

TABLE 174         ITALY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          182

TABLE 175         ITALY: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     182

TABLE 176         REST OF EUROPE: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            183

TABLE 177         REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       183

TABLE 178         REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       183

TABLE 179         REST OF EUROPE: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       184

TABLE 180         REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    184

TABLE 181         REST OF EUROPE: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       184

TABLE 182         REST OF EUROPE: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     185

TABLE 183         REST OF EUROPE: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            185

TABLE 184         ASIA PACIFIC: DIGITAL PATHOLOGY MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            186

TABLE 185         ASIA PACIFIC: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            186

TABLE 186         ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       186

TABLE 187        ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       187

TABLE 188         ASIA PACIFIC: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       187

TABLE 189        ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    187

TABLE 190         ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)     188

TABLE 191         ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          188

TABLE 192         ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER,

2022–2029 (USD MILLION)          188

TABLE 193         CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              189

TABLE 194         CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     190

TABLE 195         CHINA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       190

TABLE 196         CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       190

TABLE 197         CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     191

TABLE 198         CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      191

TABLE 199         CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 191

TABLE 200         CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          192

TABLE 201         CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     192

TABLE 202         JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              193

TABLE 203         JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     193

TABLE 204         JAPAN: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       194

TABLE 205         JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       194

TABLE 206         JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     194

TABLE 207         JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    195

TABLE 208         JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 195

TABLE 209         JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          195

TABLE 210         JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     196

TABLE 211         INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              197

TABLE 212         INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     197

TABLE 213         INDIA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       197

TABLE 214         INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       198

TABLE 215         INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 198

TABLE 216         INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      198

TABLE 217         INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 199

TABLE 218         INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          199

TABLE 219         INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     199

TABLE 220         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            200

TABLE 221         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       201

TABLE 222         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       201

TABLE 223         REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       201

TABLE 224         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      202

TABLE 225         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       202

TABLE 226         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     202

TABLE 227         REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            203

TABLE 228         LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            203

TABLE 229         LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            204

TABLE 230         LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       204

TABLE 231         LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       204

TABLE 232         LATIN AMERICA: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       205

TABLE 233         LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    205

TABLE 234         LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       205

TABLE 235         LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     206

TABLE 236         LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            206

TABLE 237         BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              207

TABLE 238         BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     207

TABLE 239         BRAZIL: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       207

TABLE 240         BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       208

TABLE 241         BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     208

TABLE 242         BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      208

TABLE 243         BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 209

TABLE 244         BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          209

TABLE 245         BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     209

TABLE 246         MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040              210

TABLE 247         MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     210

TABLE 248         MEXICO: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       211

TABLE 249         MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       211

TABLE 250         MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)     211

TABLE 251         MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    212

TABLE 252         MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION) 212

TABLE 253         MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          212

TABLE 254         MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)     213

TABLE 255         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            213

TABLE 256         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       214

TABLE 257         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       214

TABLE 258         REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       214

TABLE 259         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    215

TABLE 260         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       215

TABLE 261         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     215

TABLE 262         REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            216

TABLE 263         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)            217

TABLE 264         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            217

TABLE 265         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       218

TABLE 266         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       218

TABLE 267         MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       218

TABLE 268         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)    219

TABLE 269         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       219

TABLE 270         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     219

TABLE 271         MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            220

TABLE 272         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            220

TABLE 273         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SCANNERS,

BY TYPE, 2022–2029 (USD MILLION)       221

TABLE 274         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY TYPE, 2022–2029 (USD MILLION)       221

TABLE 275         GCC COUNTRIES: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       221

TABLE 276         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE,

BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)      222

TABLE 277         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       222

TABLE 278         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     222

TABLE 279         GCC COUNTRIES: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            223

TABLE 280         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)            223

TABLE 281         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022–2029 (USD MILLION)   224

TABLE 282         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET

FOR SOFTWARE, BY TYPE, 2022–2029 (USD MILLION)     224

TABLE 283         REST OF MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET,

BY TYPE, 2022–2029 (USD MILLION)       224

TABLE 284         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET

FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 225

TABLE 285         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY TYPE, 2022–2029 (USD MILLION)       225

TABLE 286         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)     225

TABLE 287         REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET,

BY END USER, 2022–2029 (USD MILLION)            226

TABLE 288         OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES             228

TABLE 289         DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION              231

TABLE 290         DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT              235

TABLE 291         DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT              236

TABLE 292         DIGITAL PATHOLOGY MARKET: END-USER FOOTPRINT              237

TABLE 293         DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT  238

TABLE 294         DIGITAL PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES          241

TABLE 295         DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS        242

TABLE 296         DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS,

AND APPROVALS, JANUARY 2021–MARCH 2024  245

TABLE 297         DIGITAL PATHOLOGY MARKET: DIGITAL PATHOLOGY MARKET:

DEALS, JANUARY 2021–MARCH 2024       246

TABLE 298         DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS,

JANUARY 2021–MARCH 2024      247

TABLE 299         DANAHER CORPORATION: COMPANY OVERVIEW         248

TABLE 300         DANAHER CORPORATION: PRODUCTS OFFERED          249

TABLE 301         DANAHER CORPORATION: PRODUCT ENHANCEMENTS, JANUARY 2021−JUNE 2024         250

TABLE 302         KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW         251

TABLE 303         KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED         252

TABLE 304         KONINKLIJKE PHILIPS N.V: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2024 253

TABLE 305         KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−JUNE 2024              253

TABLE 306         HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW 255

TABLE 307         HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED  256

TABLE 308         HAMAMATSU PHOTONICS K.K.: PRODUCT APPROVALS, JANUARY 2021–JUNE 2024           257

TABLE 309         HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2021–JUNE 2024      257

TABLE 310         F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 259

TABLE 311         F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED  260

TABLE 312         HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2024           261

TABLE 313         HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JUNE 2024              261

TABLE 314         SECTRA AB: COMPANY OVERVIEW        263

TABLE 315         SECTRA AB: PRODUCTS OFFERED         264

TABLE 316         SECTRA AB: DEALS, JANUARY 2021–JUNE 2024   265

TABLE 317         SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2021–JUNE 2024      266

TABLE 318         AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW         268

TABLE 319         AKOYA BIOSCIENCES, INC.: PRODUCTS OFFERED          270

TABLE 320         AKOYA BIOSCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2024           270

TABLE 321         AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021–JUNE 2024              271

TABLE 322         FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW              272

TABLE 323         FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED              273

TABLE 324         FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2021–JUNE 2024          274

TABLE 325         HOLOGIC, INC: COMPANY OVERVIEW  275

TABLE 326         HOLOGIC, INC: PRODUCTS OFFERED   276

TABLE 327         HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2021–JUNE 2024      277

TABLE 328         3DHISTECH LTD.: COMPANY OVERVIEW           278

TABLE 329         3DHISTECH LTD.: PRODUCTS OFFERED            278

TABLE 330         3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS,

JANUARY 2021–JUNE 2024           279

TABLE 331         3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2021–JUNE 2024          279

TABLE 332         APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW              280

TABLE 333         APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED              280

TABLE 334         APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS,

JANUARY 2021–JUNE 2024           281

TABLE 335         APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2021–JUNE 2024          281

TABLE 336         XIFIN, INC.: COMPANY OVERVIEW         282

TABLE 337         XIFIN, INC.: PRODUCTS OFFERED          282

TABLE 338         XIFIN, INC.: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2024              283

TABLE 339         XIFIN, INC.: DEALS, JANUARY 2021–JUNE 2024    283

TABLE 340         HURON DIGITAL PATHOLOGY: COMPANY OVERVIEW 284

TABLE 341         HURON DIGITAL PATHOLOGY: PRODUCTS OFFERED  284

TABLE 342         HURON DIGITAL PATHOLOGY: PRODUCT APPROVALS, JANUARY 2021–JUNE 2024           285

TABLE 343         HURON DIGITAL PATHOLOGY: DEALS, JANUARY 2021–JUNE 2024      285

TABLE 344         HURON DIGITAL PATHOLOGY: OTHER DEVELOPMENTS,

JANUARY 2021–JUNE 2024           285

TABLE 345         CORISTA: COMPANY OVERVIEW            286

TABLE 346         CORISTA: PRODUCTS OFFERED             286

TABLE 347         CORISTA: DEALS, JANUARY 2021–JUNE 2024       287

TABLE 348         CORISTA: OTHER DEVELOPMENTS, JANUARY 2021–JUNE 2024              287

TABLE 349         INDICA LABS: COMPANY OVERVIEW     288

TABLE 350         INDICA LABS: PRODUCTS OFFERED      288

TABLE 351         INDICA LABS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2024 289

TABLE 352         INDICA LABS: DEALS, JANUARY 2021–JUNE 2024 290

TABLE 353         OBJECTIVE PATHOLOGY SERVICES: COMPANY OVERVIEW              291

TABLE 354         OBJECTIVE PATHOLOGY SERVICES: PRODUCTS OFFERED              291

TABLE 355         OPTRASCAN, INC.: COMPANY OVERVIEW          292

TABLE 356         OPTRASCAN, INC.: PRODUCTS OFFERED           292

TABLE 357         OPTRASCAN, INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–JUNE 2024           293

TABLE 358         OPTRASCAN, INC.: DEALS, JANUARY 2021–JUNE 2024     293

TABLE 359         GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW        294

TABLE 360         GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED         294

TABLE 361         GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS,

JANUARY 2021–JUNE 2024           295

TABLE 362         AIFORIA TECHNOLOGIES OY: COMPANY OVERVIEW     296

TABLE 363         AIFORIA TECHNOLOGIES OY: PRODUCTS OFFERED      296

TABLE 364         AIFORIA TECHNOLOGIES OY: DEALS, JANUARY 2021–JUNE 2024              297

TABLE 365         PAIGE AI, INC.: COMPANY OVERVIEW   298

TABLE 366         PAIGE AI, INC.: PRODUCTS OFFERED    298

TABLE 367         PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,

JANUARY 2021–JUNE 2024           299

TABLE 368         PAIGE AI, INC.: DEALS, JANUARY 2021–JUNE 2024            299

TABLE 369         PROSCIA, INC.: COMPANY OVERVIEW   301

TABLE 370         PROSCIA, INC.: PRODUCTS OFFERED    301

TABLE 371         PROSCIA, INC.: PRODUCT ENHANCEMENTS & APPROVALS,

JANUARY 2021–JUNE 2024           302

TABLE 372         PROSCIA, INC.: DEALS, JANUARY 2021–JUNE 2024            302

LIST OF FIGURES

FIGURE 1           DIGITAL PATHOLOGY MARKET             31

FIGURE 2           RESEARCH DESIGN       34

FIGURE 3           PRIMARY SOURCES       37

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION       38

FIGURE 5           RESEARCH METHODOLOGY: HYPOTHESIS BUILDING  39

FIGURE 6           MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS              40

FIGURE 7           DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION OF DANAHER CORPORATION  41

FIGURE 8           BOTTOM-UP APPROACH           41

FIGURE 9           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   43

FIGURE 10         CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DIGITAL PATHOLOGY MARKET (2024–2029)     44

FIGURE 11         DATA TRIANGULATION METHODOLOGY         46

FIGURE 12         DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 49

FIGURE 13         DIGITAL PATHOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)          50

FIGURE 14         DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)     50

FIGURE 15         DIGITAL PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 51

FIGURE 16         GEOGRAPHIC SNAPSHOT OF DIGITAL PATHOLOGY MARKET              52

FIGURE 17         RISING INCIDENCE OF CANCER AND GROWING ADOPTION OF PATHOLOGY SOLUTIONS FOR ENHANCED LAB EFFICIENCY TO DRIVE MARKET            53

FIGURE 18         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED

FOR LARGEST MARKET SHARE IN 2023  54

FIGURE 19         UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD              55

FIGURE 20         ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD       56

FIGURE 21         DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES        57

FIGURE 22         GLOBAL CANCER INCIDENCE, 2008−2030          58

FIGURE 23         FDA-APPROVED PERSONALIZED MEDICINES, 2015−2021              63

FIGURE 24         DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS              69

FIGURE 25         DIGITAL PATHOLOGY MARKET: ECOSYSTEM ANALYSIS              70

FIGURE 26         DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS          71

FIGURE 27         EUROPE: IVDR TIMELINE           75

FIGURE 28         JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS, 2013–2023       78

FIGURE 29         MAJOR PATENTS FOR DIGITAL PATHOLOGY (2013–2023)              79

FIGURE 30         KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS              84

FIGURE 32         MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING DIGITAL PATHOLOGY ACROSS INDUSTRIES     88

FIGURE 33         IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS   91

FIGURE 34         NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT              140

FIGURE 35         EUROPE: DIGITAL PATHOLOGY MARKET SNAPSHOT   153

FIGURE 36         REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET 229

FIGURE 37         DIGITAL PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023)   230

FIGURE 38         DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023     233

FIGURE 39         DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT              234

FIGURE 40         DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2023             240

FIGURE 41         EV/EBITDA OF KEY VENDORS   243

FIGURE 42         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF DIGITAL PATHOLOGY VENDORS         243

FIGURE 43         DANAHER CORPORATION: COMPANY SNAPSHOT (2023)              249

FIGURE 44         KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)              252

FIGURE 45         HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2023)              256

FIGURE 46         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)              260

FIGURE 47         SECTRA AB.: COMPANY SNAPSHOT (2023)         264

FIGURE 48         AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)              269

FIGURE 49         FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)   273

FIGURE 50         HOLOGIC, INC: COMPANY SNAPSHOT (2023)    276